Page 262 - Read Online
P. 262

Page 16 of 23                         Parsons et al. J Cancer Metastasis Treat 2018;4:19  I  http://dx.doi.org/10.20517/2394-4722.2018.11

               Financial support and sponsorship
               This work was supported by The Brain Institute of America Foundation.


               Conflicts of interest
               Brian D. Adams is President/CEO of The Brain Institute of America and holds patent interests with AUM
               LifeTech. Authors have no other conflicts of interest to disclose. The authors declare that the research was
               conducted in the absence of any commercial or financial activities.


               Patient consent
               Not applicable.

               Ethics approval
               Not applicable.

               Copyright
               © The Author(s) 2018.


               REFERENCES
               1.   DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-18.
               2.   Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013;18:43-73.
               3.   Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res 2016;23:205-17.
               4.   De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
               5.   Chiang SP, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol 2016;311:C1-14.
               6.   Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008;272:177-85.
               7.   Irmisch A, Huelsken J. Metastasis: new insights into organ-specific extravasation and metastatic niches. Exp Cell Res 2013;319:1604-10.
               8.   Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, Barbero D, Palumbo A, Passera R, Boccadoro M, Ritgen M,
                   Gökbuget N, Zheng J, Carlton V, Trautmann H, Faham M, Pott C. Next-generation sequencing and real-time quantitative PCR for
                   minimal residual disease detection in B-cell disorders. Leukemia 2014;28:1299-307.
               9.   Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
               10.  Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. Epithelial-mesenchymal transition induced by growth suppressor
                   p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008;68:10377-86.
               11.  Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol
                   2009;174:1588-93.
               12.  Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev
                   Cancer 2009;9:265-73.
               13.  Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer.
                   Development 2005;132:3151-61.
               14.  Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
               15.  Burger GA, Danen EH, Beltman JB. Deciphering epithelial-mesenchymal transition regulatory networks in cancer through
                   computational approaches. Front Oncol 2017;7:162.
               16.  Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol
                   2012;22:234-49.
               17.  Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis.
                   Cancer Metastasis Rev 2014;33:1-16.
               18.  Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest 2017;127:761-71.
               19.  Abdul-Rahman U, Győrffy B, Adams BD. linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer.
                   Transcription 2018;9:17-29.
               20.  Adams BD, Slack FJ. MicroRNA Signatures as Biomarkers in Cancer. In: eLS. Chichester: John Wiley & Sons Ltd; 2015.
               21.  Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha)
                   and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21:1132-47.
               22.  Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular
                   response to ionizing radiation. Oncogene 2017;36:512-24.
               23.  Lang MF, Yang S, Zhao C, Sun G, Murai K, Wu X, Wang J, Gao H, Brown CE, Liu X, Zhou J, Peng L, Rossi JJ, Shi Y. Genome-wide
                   profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One
                   2012;7:e36248.
   257   258   259   260   261   262   263   264   265   266   267